Pfizer Ltd. — Regulatory Filings 2020

Jul 14, 2020

==> picture [63 x 37] intentionally omitted <==

Limited

The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 14, 2020

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Dalal Street, Fort Plot No. C/1, G Block Mumbai - 400 001 Bandra-Kurla Complex, Bandra (E) Scrip Code: 500680 Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’)

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the year ended March 31, 2020.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

==> picture [112 x 55] intentionally omitted <==

Prajeet Nair Company Secretary

Encl: A/a

==> picture [11 x 21] intentionally omitted <==

CIN: L24231MH1950PLC008311

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company: Pfizer Inc., USA

B. Companies collectively exercising significant influence:

Pfizer East India B.V., Netherlands Wyeth LLC, USA Wyeth Holdings Corporation, USA John Wyeth & Brother Limited, UK Warner - Lambert Company, LLC, USA Parke - Davis & Company, LLC, USA Pharmacia Corporation, USA [Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the year

Pfizer Products India Private Limited, India Pfizer Innovative Supply Point International BVBA, Belgium Pfizer Service Company BVBA, Belgium Pfizer Worldwide Services, Ireland Pfizer Asia Manufacturing PTE, Singapore Pfizer Canada Inc

D. Key managerial personnel

Mr. S. Sridhar - Managing Director

Mr. Milind Patil - Wholetime Director & Chief Financial Officer

Mr. Vivek Dhariwal - Wholetime Director ( upto 14 February 2020)

Mr. Samir Kazi (w.e.f 14 February 2020)

Dr. Anurita Majumdar - Wholetime Director ( upto 8 March 2019)

Mr. R A Shah - Independent Director

Mr. Pradip Shah - Independent Director

Mr. Uday Khanna - Independent Director

Mr. Sunil Lalbhai - Independent Director Ms.Meena Ganesh - Independent Director

E. Relative of Key managerial personnel

Mr. Akhilesh Iyer ( w.e.f 20 February 2019)

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions (Continued)

II. Transactions during the year and balances outstanding as at the year end with the related parties are as follows:

	31 March 2020	31 March 2020	31 March 2019
	No. Nature of transactions Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total		Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total
	1 Service income - - 55.19 55.19 2 Recovery of expenses 0.54 0.03 0.19 0.76 3 Purchase of stock-in-trade - - 393.41 393.41 4 Purchase of raw / bulk materials - - 115.05 115.05 5 Reimbursement of expenses - - - - 6 Dividend in respect of the year ended 31 March 2020/ 2019 - 65.77 - 65.77 7 Liablitywritten back - 1.42 8.59 10.01		0.37 - 50.56 50.93 - - 0.36 0.36 - - 396.42 396.42 - - 49.98 49.98 0.27 - - 0.27 - 58.49 - 58.49 - - - -
	31 March 2020		31 March 2019
	No. Nature of transactions Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total		Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total
	8 Outstanding as at the year end – Due from 0.54 0.09 20.99 21.62 9 Outstandingas at theyear end – Due to 11.18 6.47 271.20 288.85		0.33 0.06 19.21 19.60 10.52 7.84 254.97 273.33
	Key managerial personnel No. Nature of transactions Year ended 31 March 2020 Year ended 31 March 2019
	No. Nature of transactions Year ended 31 March 2020 Year ended 31 March 2019
	1 Remuneration to keymanagementpersonnel 9.22* 10.50

• Excludes amounts payable to key management personnel towards gratuity and compensated absences.

Details of material transactions during the year:

	Details of material transactions during the year:
	Year ended 31 March 2020 Year ended 31 March 2019
	a) Service income
	Pfizer Products India Private Limited 25.60 23.22 Pfizer Worldwide Services 29.59 27.34
	b) Recovery of expenses
	Pfizer Products India Private Limited 0.19 0.34
	Pfizer Inc., USA 0.54 - c) Purchase of stock in trade
	Pfizer Innovative Supply Point Intl BVBA, Belgium 80.21 258.18 Pfizer Service Company BVBA, Belgium 300.36 131.93 d) Purchase of raw/ bulk materials Pfizer Service Company BVBA, Belgium 111.62 46.87
	e) Reimbursement of expenses
	Pfizer Inc., USA - 0.27
	f) Dividend paid
	Pfizer East India B.V. 40.92 36.37 Wyeth LLC, USA 12.64 11.24
	g) Remuneration to key management personnel
	S. Sridhar 4.11 3.55 Milind Patil 2.10 1.59 Vivek Dhariwal 1.88 2.53 Samir Kazi 0.16 - Dr. Anurita Majumdar - 1.96

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions (Continued)

	Related party transactions(Continued)
		As on 31 March 2020	As on 31 March 2019
	h) Outstanding as at the year end due from Pfizer Worldwide Services Pfizer Products India Private Limited, India i) Outstanding as at the year end due to	5.70 15.29	5.47 13.74
	Pfizer Innovative Supply Point Intl BVBA, Belgium	15.81	62.49
	Pfizer Service Company BVBA, Belgium Pfizer Export Company, Ireland	152.55 82.85	83.97 84.70